Aura Biosciences (AURA) Assets Average (2021 - 2026)

Aura Biosciences (AURA) has 6 years of Assets Average data on file, last reported at $153.6 million in Q1 2026.

• Quarterly Assets Average fell 9.11% year-over-year to $153.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153.6 million (down 9.11% YoY) and the FY2025 annual result came in at $176.0 million, down 19.57% from the prior year.
• Assets Average retreated to $153.6 million in Q1 2026, from $179.7 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $245.0 million in Q1 2024 to a low of $139.1 million in Q3 2022.
• A 5-year average of $187.7 million and a median of $186.3 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average soared 46.4% — and 2025, when it slumped 31.05%.
• Tracing AURA's Assets Average over 5 years: stood at $183.5 million in 2022, then advanced by 18.46% to $217.4 million in 2023, then fell by 10.81% to $193.9 million in 2024, then decreased by 7.32% to $179.7 million in 2025, then decreased by 14.56% to $153.6 million in 2026.
• The last three Assets Average figures came in at $153.6 million (Q1 2026), $179.7 million (Q4 2025), and $197.2 million (Q3 2025), per Business Quant data.